Nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS)

Abstract

The J-POPS, a nationwide prospective cohort study that enrolled approximately 40 % of all PI cases in Japan, will provide highly reliable evidence, including outcomes and quality of life, after long-term follow-up.

Urinary and Rectal Toxicity Profiles After Permanent Iodine-125 Implant Brachytherapy in Japanese Men: Nationwide J-POPS Multi-institutional Prospective Cohort Study

“…Most of the institutions that participated in this study adopted peripheral loading or modified peripheral loading, which reduces the dose administered to the neighboring urethra. This distribution yields high peripheral doses without substantially increasing the urethral dose (16). Our results are similar to those of Keyes et al (22), who reported that higher dose was associated with higher late urinary toxicity.…”

“…Androgen deprivation therapy was recommended for patients who had prostate volume >40 mL for a short duration and for those who had high-risk disease for several months. The details of the study and the baseline characteristics of the initial subjects who were enrolled to participate in this study from July 2005 to June 2007 have been described by our study group (16).…”

“…Over the course of 5.5 years, 6927 patients were enrolled to participate in this study (16). This is a preliminary report that evaluates the urinary and rectal toxicities of the subjects enrolled during the first 2 years, and it has a particular focus on the urinary and rectal toxicity profiles of subjects who received either PI alone or a combination of PI and external beam radiation therapy (EBRT).…”

Permanent prostate brachytherapy with or without supplemental external beam radiotherapy as practiced in Japan: Outcomes of 1300 patients

“…This special situation arises from a general anxiety about radiation risk among the population. Therefore, we usually had to reduce the prostate volume to around 30 cc with NADT for radiation safety (12). Now we can manage to treat a patient with a prostate of 40e60 cc without NADT, following the regulation (22).…”

“…About 27,000 cases have been treated with permanent prostate BT in 109 institutions between 2003 and 2013 (12). The 125 I prostate BT program at the Tokyo Medical Center commenced in 2003.…”